- Home
- TPST vs RAND Comparison
TPST vs RAND Comparison
Compare TPST & RAND Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TPST
- RAND
- Stock Information
- Founded
- TPST 2011
- RAND 1969
- Country
- TPST United States
- RAND United States
- Employees
- TPST N/A
- RAND N/A
- Industry
- TPST Biotechnology: Pharmaceutical Preparations
- RAND Finance: Consumer Services
- Sector
- TPST Health Care
- RAND Finance
- Exchange
- TPST Nasdaq
- RAND Nasdaq
- Market Cap
- TPST 42.3M
- RAND 41.3M
- IPO Year
- TPST N/A
- RAND N/A
- Fundamental
- Price
- TPST $9.21
- RAND $14.00
- Analyst Decision
- TPST Hold
- RAND
- Analyst Count
- TPST 3
- RAND 0
- Target Price
- TPST $30.00
- RAND N/A
- AVG Volume (30 Days)
- TPST 33.2K
- RAND 3.0K
- Earning Date
- TPST 11-05-2025
- RAND 11-07-2025
- Dividend Yield
- TPST N/A
- RAND 11.94%
- EPS Growth
- TPST N/A
- RAND N/A
- EPS
- TPST N/A
- RAND N/A
- Revenue
- TPST N/A
- RAND $7,327,287.00
- Revenue This Year
- TPST N/A
- RAND N/A
- Revenue Next Year
- TPST N/A
- RAND N/A
- P/E Ratio
- TPST N/A
- RAND N/A
- Revenue Growth
- TPST N/A
- RAND N/A
- 52 Week Low
- TPST $5.35
- RAND $13.40
- 52 Week High
- TPST $13.65
- RAND $31.89
- Technical
- Relative Strength Index (RSI)
- TPST 42.88
- RAND 50.04
- Support Level
- TPST $8.51
- RAND $13.76
- Resistance Level
- TPST $9.75
- RAND $14.00
- Average True Range (ATR)
- TPST 0.68
- RAND 0.23
- MACD
- TPST -0.09
- RAND 0.06
- Stochastic Oscillator
- TPST 33.73
- RAND 100.00
About TPST Tempest Therapeutics Inc.
Tempest Therapeutics Inc is a late-stage develpment biotechnology company developing small molecule therapeutics to treat cancer through mechanisms that directly kill tumor cells and activate tumor-specific immunity. Its clinical-stage therapeutic product candidates are TPST-1120 and TPST-1495 which are clinical-stage molecules designed to inhibit their respective targets.
About RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.